Dilan Athauda (@DilanAthauda) profile picture

Neurologist & Scientist, UCL & The National Hospital for Neurology & Neurosurgery

Joined January 2019
Photo by Dilan Athauda (@DilanAthauda)
GLP-1 receptor agonists have transformed metabolic disease. In neurodegeneration, results are promising but mixed. We review mechanistic data, trial evidence, and the need for biologically informed patient stratification across PD, AD and related disorders. Our @JCIJournal Review: jci.org/articles/view/194745 @foltynie @LabGandhi @UCLIoN @TheCrick @ScienceofPD
1
10
506
Dilan Athauda retweeted
Is insulin resistance an early modifying factor for the later occurrence of Parkinson's disease? All the talk of GLP-1 diabetes drugs begs the question. Alise Zagare and colleagues write about their work in the latest issue of @MDJ_Journal. Key Points: - The authors point to studies showing that central insulin resistance might have big role in Parkinson's. - Why does it emerge? - They looked at insulin resistance and its role in GBA1 mutations. - They used mini-brains in a dish (organoids). - Insulin signaling pathway genes were dysregulated. - They rescued some of the effect with a knockdown of FOXO1. - They point to using the anti-diabetic drug Pioglitazone in GBA-PD. My take: This is an interesting study and a fascinating question. Pioglitazone failed a clinical trial for Parkinson's disease in general; however maybe it needs to be personalized for those only w/GBA Parkinson's. It is really hard to pull off because of the ~10% penetrance of GBA, the difficulty in recruiting folks, and the heterogeneity of presentations. It will be interesting to see if the science holds up in human. Very cool! Are we getting closer to personalization of therapies? movementdisorders.onlinelibr… #Parkinson
9
25
2,768
Interesting @biorxivpreprint from @DilanAthauda @LabGandhi & colleagues reports GLP-1R agonist exenatide restores insulin signalling (via restoration of Akt & suppression of MAPK pathways) & reverses synucleinopathy toxicity; Implications for #Parkinsons? biorxiv.org/content/10.1101/…
1
1
938
Identification of target cell types and mechanisms through which GLP-1R agonism may represent a disease modifying strategy in synucleinopathies #Parkinsons disease biorxiv.org/content/10.1101/… #insulin resistance
4
21
3,671
Machine learning can accurately predict subtypes of Parkinson’s disease using images of patient-derived stem cells, reports a study published in @NatMachIntell. go.nature.com/3qDl3yO
19
75
31,970
The @LabGandhi team took part in an intensive coding course when the pandemic disrupted their research – and now they’ve published work with @faculty_ai showing that computer models can classify types of Parkinson’s from images of stem cells 🧠 @UCLIoN crick.ac.uk/news/2023-08-10_…
4
15
4
31
15,327
New research presents MAPKAPK2 as a potential early diagnostic biomarker of diseases associated with the aggregation of α-synuclein, such as #Parkinsons; nature.com/articles/s41531-0…
4
8
1,705
New paper from @GurvirVirdi @MineeChoi @LabGandhi & collaborators uses hiPSCs to delve into the "temporal sequence of SNCA-induced pathophysiological events in order to discover early, & likely causative, events" in #Parkinsons; A lot to unpack here! nature.com/articles/s41531-0…
11
23
🎉Our latest paper from @GurvirVirdi @LabGandhi highlighting a new mDA neuron #iPSC #Parkinsons model with protein aggregation and calcium dysregulation molecular hallmarks. Congratulations team!! @ASAP_Research #asynuclein #openscience #collaboration nature.com/articles/s41531-0…
5
1
13
JOB ALERT We have a new Research Technician role available with @LabGandhi To apply atsv7.wcn.co.uk/search_engin…
Ooooh, look at that: @MicheleTagliati & colleagues have made a preprint of results of the Phase II, randomized, double-blinded, placebo-controlled clinical trial of Liraglutide in #Parkinsons available - Study funded by @CureParkinsonsT papers.ssrn.com/sol3/papers.…
1
5
1
16
Dilan Athauda retweeted
A brilliant meeting for ACORD fellows yesterday, chaired by @suvankarpal at @MRCCTU . A lot of exciting novel trial-related work going on across neurodegenerative diseases. And always incredible to hear the STAMPEDE trial success story from @MaxParmarMRCUCL . – at Islington, London
Dilan Athauda retweeted
Our latest work is finally out!! Congratulations to a fantastic team of collaborators @LabGandhi @KlenermanLab @MathewHHorrocks @KunathLab @EM_STP and our labs @UCLIoN and @TheCrick and huge thanks to our funders @The_MRC and @ASAP_Research nature.com/articles/s41593-0…
1
18
2
87
Our new paper in @MDJ_Journal, Type 2 diabetes is associated with faster progression of motor and non-motor symptoms in #Parkinsons..thank you to all the participants in PRoBaND study and the clinical consortium! @CureParkinsonsT @ParkinsonsUK tinyurl.com/5n7pnpu7
2
20
2
34
An exciting opportunity for any post-docs interested in exploring metabolism & neurodegeneration to work with me in the Gandhi Lab - happy to chat if interested (closing date 19th Jan) @CureParkinsonsT @UKEVSoc @TheCrick @LabGandhi
Great opportunity for a post-doctoral research fellow at @TheCrick @LabGandhi The project utilizes #ExtracellularVesicles to understand the pathophysiological basis of the interaction between metabolism and neurodegeneration. Reach out if interested! atsv7.wcn.co.uk/search_engin…
Great opportunity for a post-doctoral research fellow at @TheCrick @LabGandhi The project utilizes #ExtracellularVesicles to understand the pathophysiological basis of the interaction between metabolism and neurodegeneration. Reach out if interested! atsv7.wcn.co.uk/search_engin…